The Webinar Training Pass

Now get all the training you need – all in one place, and all for one low price!

The FDAnews Webinar Training Pass program gives you year-round unrestricted access to any of the hundreds of webinars listed below. These training programs feature top consultants, expert speakers and FDA officials.

PLUS, subscribers get automatic access to all our new training programs for the next 12 months – that’s more than 50 new programs a year!

If you are already a Training Pass member login below and then scroll down to view the list in date order or narrow your search by keyword or category. Viewing the webinar is easy… simply identify the webinar you want to watch, click on the title and the video will begin. If you would like to view or download the presentation materials separately from the video click the "Download Presentation" link.

Select webinars have been pre-approved by RAPS as eligible for up to 1.5 credits toward a participant’s RAC recertification. Please enter keyword RAPS below for a list of eligible on-demand webinars.

Already have an account?   Login Here.

Webinar Training Pass

Recorded on: April 10, 2018

Description: Attorney Katlin Backfield outlines recent regulatory developments regarding REMS and discusses possible outcomes. She covers:

  • Commissioner Gottlieb’s emphasis on drug pricing and how it will affect the development of single shared-system REMS;
  • Bills in the congressional pipeline and their odds on passage; and
  • Recent trends in FDA’s REMS-related enforcement.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Katlin Backfield, Attorney and Consultant, Backfield PLLC

Recorded on: March 29, 2018

Description: Product management experts Daniel Matlis and Mike Jovanis discuss change management best practices and how to leverage technology for an effective and efficient change control process, including:

  • Roles and responsibilities;
  • A framework to systematically assess global operational and regulatory impact;
  • Structuring and implementing change releases in a global environment;
  • Streamlining processes between departments; and
  • Gaining better intelligence to improve decisionmaking.

Presentation: Download the presentation

Transcript: Download the transcript

Speakers: Daniel R. Matlis, Founder and President, Axendia, and Mike Jovanis, Vice President-Vault Quality, Veeva Systems

Recorded on: March 27, 2018

Description: Clinical trial management expert Wes Martz discusses ways to maximize your site feasibility and selection process. He covers:

  • How to pre-identify most likely high-performing sites based on available historical performance data;
  • Advice for tightening up feasibility questionnaires to reduce site burden;
  • Examples of common “don’ts” in questionnaire development; and
  • Insights into response data review and how to handle discrepancies.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Wes Martz, Associate Director, Clinical Services, ePharmaSolutions

Recorded on: March 20, 2018

Description: Pharmacovigilance expert Angela Pitwood explains how to use analytical data techniques in pharmacovigilance. She discusses:

  • What Big Data is and isn’t, and how you can use it to improve your pharmacovigilance program;
  • How the use of natural language can expedite the accurate reporting of adverse events;
  • How you can train machines to report whether drugs were a determining factor in an adverse event; and
  • What the future might bring in terms of new techniques for inputting and analyzing safety data.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Angela Pitwood, Vice President of Pharmacovigilance, Vigilare

Recorded on: March 20, 2018

Description: Research ethics specialist Luke Gelinas discusses the ethical and regulatory issues involved with paying research subjects and proposes a practical framework that can guide the design and evaluation of payment offers. He covers:

  • Reasons to pay research participants and the role that payment plays in facilitating recruitment;
  • Risk of undue influence and the possibility that payment might motivate deception about eligibility;
  • Current practices regarding payment of research participants, such as payment rates and frequency of payment in various types of clinical research; and
  • Methods of calculating payment amounts, including distinguishing different reasons for offering payment, such as reimbursement, compensation for time, or recruitment incentive.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Luke Gelinas, Senior Researcher with Petrie-Flom Center at Harvard Law School

Recorded on: March 7, 2018

Description: Former FDA counsel Mark Schwartz gives an update on where the FDA stands currently on such issues as data integrity, inspection practices and quality metrics. He discusses:

  • Why the FDA is stepping up pursuit of data integrity issues now;
  • How FDA may invoke the adulteration provision when companies balk at inspections;
  • Why the agency might request records in advance or in lieu of an inspection; and
  • The status of the draft quality metrics initiative.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Mark I. Schwartz, Director, Hyman, Phelps & McNamara

Recorded on: March 6, 2018

Description: UDI architect Jay Crowley explains the FDA’s new guidance on marking devices with unique device identifiers. He discusses:

  • How the definition of “intended to be reprocessed” for purposes of UDI direct marking has changed from draft to final rule;
  • Whether “single patient use” devices fall under the direct mark requirement;
  • What the final guidance says about how consigned or loaned devices will be treated for the purposes of the direct mark requirement; and
  • FDA recordkeeping requirements for devices that must be directly marked.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Jay Crowley, Vice President, Unique Device Identification Services and Solutions, USDM Life Sciences

Recorded on: March 1, 2018

Description: Clinical trial management experts Richard Young and Ken Getz discuss the impact of real-world evidence on traditional data management systems. They cover:

  • Best practices for integrating real-world evidence into the different phases of clinical trials;
  • Utilization of real-world evidence to support healthcare coverage decisions;
  • How medical product developers are using real-world data to support clinical trial design; and
  • Evolving implementation of the 21st Century Cures Act’s provisions regarding use of real-world evidence.

Presentation: Download the presentation

Transcript: Download the transcript

Speakers: Richard Young, VP, Vault EDC, Veeva Systems, and Ken Getz, Associate Professor and Director, CSDD, Tufts University and Founder and Board Chair, CISCRP

Recorded on: Feb. 28, 2018

Description: Biosafety experts Lindsay McNair and Daniel Kavanagh discuss the science of gene therapy and gene editing and the most important ethical challenges inherent in clinical research in rare diseases specific to gene therapy research. Topics include:

  • Basic science of gene replacement therapies;
  • Examples of therapies in development for rare diseases;
  • Specific challenges in the use of gene therapy to treat rare diseases; and
  • Ethical issues in research of patients with rare diseases.

Presentation: Download the presentation

Transcript: Download the transcript

Speakers: Lindsay McNair, Chief Medical Officer, WIRB-Copernicus Group, and Daniel Kavanagh, Senior Director of Biosafety and Gene Therapy, WCG Biosafety

Recorded on: Feb. 22, 2018

Description: Quality systems expert Dan O’Leary explains his supplier metrics system, which includes determining your expectations of the supplier, converting them into measurable characteristics, defining the measurement method, and setting the target. He discusses:

  • Requirements from ISO 13485:2016 and additional guidance from the ISO 13485:2016 Handbook;
  • Inspection tasks from the FDA’s QSIT;
  • Audit tasks from the MDSAP Audit Model;
  • Incorporating predictive metrics; and
  • Markers of poor performance.

Presentation: Download the presentation

Transcript: Download the transcript

Speaker: Dan O’Leary, President, Ombu Enterprises LLC